Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Se...

Descripción completa

Detalles Bibliográficos
Autores principales: COSTANZO, Antonio, RUSSO, Filomena, GALLUZZO, Marco, STINGENI, Luca, SCUDERI, Roberta, ZICHICHI, Leonardo, PAPINI, Manuela, DI COSTANZO, Luisa, CONTI, Andrea, BURLANDO, Martina, CHIRICOZZI, Andrea, GAIANI, Francesca Maria, MUGHEDDU, Cristina, MUSUMECI, Maria Letizia, GISONDI, Paolo, PIASERICO, Stefano, DAPAVO, Paolo, VENTURINI, Marina, PAGNANELLI, Gianluca, AMERIO, Paolo, POTENZA, Concetta, PERIS, Ketty, CANTORESI, Franca, TREVISINI, Sara, LOCONSOLE, Francesco, OFFIDANI, Annamaria, MERCURI, Santo Raffaele, LORA, Viviana, PRIGNANO, Francesca, BARTEZAGHI, Marta, OLIVA, Giovanni, ALOISI, Elisabetta, ORSENIGO, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2021
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425609/
https://www.ncbi.nlm.nih.gov/pubmed/33903916
http://dx.doi.org/10.2340/00015555-3816
Descripción
Sumario:Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.

Ejemplares similares